[Evolution in vitamin D treatment after debut of sevelamer hydrochloride in chronic renal failure patients].
Newly developed sevelamer hydrochlorid (Sev-HCl) has been recognized to show the effective control of the hyperphosphatemia in chronic renal failure patients, without elevation of serum Ca, Mg, and Al as well. Then, Sev-HCl has been expected to evolute the vitamin D treatment, and to reduce the ectopic calcifications through lowering Ca x P products. Although, relatively high frequent abdominal adverse effects in Sev-HCl treatment were reported, including life-threatening bowel occlusions or bowel perforations. It is important to use the appropriate dose of Sev-HCl avoiding the abdominal adverse effects.